文献速递免疫规划卫生政策与健康促进

2015/16年北半球流感季节英国与芬兰对Vaxigrip和Intanza 15 µg的被动增强安全性监测

Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
PubMed 文献 · Euro Surveill · 2017-01-01

为符合欧洲药品管理局临时指导要求,在英国和芬兰对Vaxigrip和Intanza 15 µg开展被动增强安全性监测(ESS),以近实时发现流感疫苗株组成年度更新后反应原性是否升高。Vaxigrip接种者1012人中32人(3.2%)报告122例疑似不良反应,其中110例发生在接种后7天内;Intanza 15 µg接种者1017人中31人(3.0%)报告114例,其中99例发生在7天内。结果与两疫苗已知安全性特征一致,未显示反应原性或安全性方面的变化。

要点

  • Vaxigrip接种者1012人中32人(3.2%)报告122例疑似不良反应,其中110例在接种后7天内发生
  • Intanza 15 µg接种者1017人中31人(3.0%)报告114例疑似不良反应,其中99例在接种后7天内发生
  • 结果与两疫苗已知安全性特征一致,未显示反应原性或安全性担忧的变化

核心结论

  • 结果与Vaxigrip和Intanza 15 µg的已知安全性特征一致,未显示反应原性或安全性担忧的变化。
  • 该被动ESS显示数据报告得到改善,并证明其符合卫生当局要求;所有利益相关方正在讨论对该方法的进一步微调。

研究设计与样本

  • 在英国和芬兰开展的被动增强安全性监测(ESS),针对Vaxigrip和Intanza 15 µg,以符合欧洲药品管理局临时指导。
  • Vaxigrip接种者n=1012,Intanza 15 µg接种者n=1017。

主要发现

  • Vaxigrip接种者(n=1012)中32人(3.2%)报告共122例疑似不良反应,其中110例发生在接种后7天内。
  • Intanza 15 µg接种者(n=1017)中31人(3.0%)报告共114例疑似不良反应,其中99例发生在接种后7天内。

局限性

  • 所有利益相关方正在讨论对该方法的进一步微调。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Enhanced safety surveillance (ESS) was conducted in the United Kingdom and Finland for Vaxigrip and Intanza 15 µg to comply with the European Medicines Agency interim guidance aimed to detect any potential increase in reactogenicity in near real time following the annual update of the influenza vaccine strain composition. This pilot passive ESS was established to strengthen safety monitoring by facilitating spontaneous vaccinee reports and estimating near real-time vaccinee exposure. The primary objective was to estimate the reporting rates of suspected adverse reactions (ARs) occurring within 7 days post vaccination during the northern hemisphere 2015/16 influenza season. Among the Vaxigrip vaccinees (n = 1,012), 32 (3.2%) reported a total of 122 suspected ARs, including 110 suspected ARs that occurred within 7 days post vaccination. Among the Intanza 15 µg vaccinees (n = 1,017), 31 (3.0%) reported a total of 114 suspected ARs, including 99 that occurred within 7 days post-vaccination. These results were consistent with the known safety profile of the two vaccines and did not show any change in reactogenicity or safety concerns. This passive ESS showed improved data reporting and demonstrated its suitability to health authorities' requirements; further fine tuning of the methodology is under discussion between all stakeholders.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Bricout H, Chabanon AL, Souverain A, et al. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017. PMID: 28494843. doi:10.2807/1560-7917.ES.2017.22.18.30527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。